A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

被引：26

作者：

Hainsworth, John D. ^{[1
,2
]}

Arrowsmith, Edward R. ^{[1
,2
]}

McCleod, Michael ^{[1
,3
]}

Hsi, Eric D. ^{[4
]}

Hamid, Oday ^{[5
]}

Shi, Peipei ^{[5
]}

Lin, Boris K. ^{[5
]}

Fayad, Luis E. ^{[6
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN 37203 USA

[2] Tennessee Oncol PLLC, Nashville, TN USA

[3] Florida Canc Specialists, Ft Myers, FL USA

[4] Cleveland Clin, Cleveland, OH 44106 USA

[5] Eli Lilly & Co, Indianapolis, IN 46285 USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

LEUKEMIA & LYMPHOMA | 2016年 / 57卷 / 01期

关键词：

BETA II EXPRESSION; KINASE; CHEMOTHERAPY; INHIBITOR;

D O I：

10.3109/10428194.2015.1045898

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：216 / 218

页数：3

共 13 条

[1] Protein kinase C-β II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab [J].

Chaiwatanatorn, Kritika ;

Stamaratis, Georgia ;

Opeskin, Ken ;

Firkin, Frank ;

Nandurkar, Harshal .

LEUKEMIA & LYMPHOMA, 2009, 50 (10) :1666-1675

[2] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[3] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[4]

Coiffier B, 2007, HEMATOLOGY M REPORTS, V1, P27

[5]

Crump M, 2013, BLOOD, V122

[6] Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR [J].

Dutton, A ;

Reynolds, GM ;

Dawson, CW ;

Young, LS ;

Murray, PG .

JOURNAL OF PATHOLOGY, 2005, 205 (04) :498-506

[7] Diffuse Large B-Cell Lymphoma [J].

Friedberg, Jonathan W. ;

Fisher, Richard I. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2008, 22 (05) :941-+

[8] The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts [J].

Graff, JR ;

McNulty, AM ;

Hanna, KR ;

Konicek, BW ;

Lynch, RL ;

Bailey, SN ;

Banks, C ;

Capen, A ;

Goode, R ;

Lewis, JE ;

Sams, L ;

Huss, KL ;

Campbell, RM ;

Iversen, PW ;

Neubauer, BL ;

Brown, TJ ;

Musib, L ;

Geeganage, S ;

Thornton, D .

CANCER RESEARCH, 2005, 65 (16) :7462-7469

[9]

King LB, 1999, J IMMUNOL, V162, P2655

[10] Diagnosis and treatment of diffuse large B-cell lymphoma [J].

Mey, Ulrich ;

Hitz, Felicitas ;

Lohri, Andreas ;

Pederiva, Stefanie ;

Taverna, Christian ;

Tzankov, Alexander ;

Meier, Oliver ;

Yeow, Karen ;

Renner, Christoph .

SWISS MEDICAL WEEKLY, 2012, 142

← 1 2 →